目的：探讨活血化瘀方剂对慢性盆腔炎（CPID）模型大鼠T 细胞亚群和红细胞免疫功能的影响。方法：75 只Wistar 大鼠，用混合菌加机械损伤造模法建立CPID 大鼠模型。将大鼠分为正常组、假手术组、模型组、桂枝茯苓胶囊组、少腹逐瘀胶囊对照组、金刚藤胶囊对照组，桂枝茯苓胶囊对照组、少腹逐瘀胶囊组、金刚藤胶囊对照组分别给予相应药物灌胃。检测各组大鼠脾脏CD3+、CD4+、CD8+ T 细胞以及CD4+CD25+调节性T 细胞（Treg）数量百分比，血红细胞C3b 受体花环率（RBC-C3bRR）及红细胞免疫复合物花环率（RBC-ICR）。结果：各组药物均能提高模型鼠CD3+、CD4+ T 细胞数量百分比及CD4 /CD8 T 细胞比值（P<0.05），均能降低CD8+ T 细胞数量百分比（P<0.05）。桂枝茯苓胶囊能明显降低模型大鼠异常升高的CD4+CD25+ Treg 数量百分比（P<0.05）。桂枝茯苓胶囊及少腹逐瘀胶囊使模型大鼠RBC-C3bRR 升高（P<0.05），RBC-ICR 降低（P<0.05）。结论：活血化瘀方通过调控T 细胞亚群和红细胞的免疫功能，达到治疗CPID 的目的。

This study was aimed to explore the effect on immunological function of T lymphocyte subpopulation and erythrocyte by the method of promoting blood flow and dissipating phlegm of rat with chronic pelvic inflammatory disease (PID). A mixture of bacteria combined with mechanical injury was used in the establishment of a total of 75 Wistar chronic PID rat models. The rats were divided into the normal group, sham-operation group, model group,Gui-Zhi Fu-Ling Capsule (GZFLC) group, Shao-Fu Zhu-Yu Capsule (SFZYC) group, Jin-Gang-Teng Capsule(JGTC) group, and the control group of GZFLC, SFZYC, and JGTC. Intragastric administration of each medication was given according to different groups. The percentage of amount of CD3+, CD4+, CD8+ and CD4+CD25+ regulatory T cell (Treg) in the spleen of rats was observed in each group. The RBC-C3bRR and RBC-ICR in the blood serum of rats were also observed. The results showed that medications used in all treatment group significantly increased the percentage of amount of CD3+, CD4+ and CD4/CD8 ratio (P < 0.05) and reduced the percentage of amount of CD8+(P < 0.05). GZFLC has significantly decreased the abnormal increased percentage of the amount of CD4+CD25+ Treg.GZFLC and SFZYC significantly increased RBC-C3bRR (P < 0.05) and decreased RBC-ICR (P < 0.05). It was concluded that the prescription of promoting blood flow and dissipating phlegm can treatment chronic PID by adjusting immunity of T lymphocyte subpopulation and erythrocyte.

科学技术部国家“十一五”科技支撑计划项目（2007BAI20B013-01）：慢性盆腔炎中医四联疗法的优化及诊疗规范研究——慢性盆腔炎中医综合疗法的优化研究，负责人：刘瑞芬。